{'fraction_non_alphanumeric': 0.02140309155766944, 'fraction_numerical': 0.0035671819262782403, 'mean_word_length': 6.135593220338983, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Long‐term efficacy of bevacizumab and irinotecan in recurrent pediatric glioblastoma

A 5‐year‐old boy with glioblastoma relapsed soon after postoperative irradiation in combination with temozolomide. Second‐line chemotherapy was also ineffective; therefore, the bevacizumab and irinotecan were given after a third gross‐total resection of the tumor. Treatment was interrupted for 1 month due to development of posterior reversible encephalopathy syndrome, but was re‐initiated at a lower dose of bevacizumab with prolonged intervals between treatments. The patient was alive and disease free 2 years after initial diagnosis. Bevacizumab and irinotecan are a promising regimen for pediatric cases of recurrent glioblastoma after gross‐total resection, although the optimal treatment schedule must be determined on a patient‐by‐patient basis.